• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Cachexia, Sarcopenia and Muscle >One‐year intranasal application of growth hormone releasing peptide‐2 improves body weight and hypoglycemia in a severely emaciated anorexia nervosa patient
【24h】

One‐year intranasal application of growth hormone releasing peptide‐2 improves body weight and hypoglycemia in a severely emaciated anorexia nervosa patient

机译：鼻内应用生长激素释放肽2一年可改善严重消瘦的神经性厌食症患者的体重和低血糖

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

AbstractBackgroundIn Japan, growth hormone releasing peptide-2 (GHRP-2) is clinically used as a diagnostic agent for growth hormone secretion deficiency, but the therapeutic application of GHRP-2 has not been studied in anorexia nervosa. GHRP-2 reportedly exhibits agonistic action for ghrelin receptor and increases food intake.MethodsWe administered GHRP-2 to a patient with a 20-year history of anorexia nervosa to determine whether GHRP-2 treatment increases food intake and body weight. GHRP-2 was administered before every meal by an intranasal approach for 1 year.ResultsAlthough the patient reported a decreased fear of eating and decreased desire to be thin by our previous treatment, she was unable to increase food intake or body weight because of digestive tract dysfunction. Vomiting after meals caused by delayed gastric emptying and incurable constipation were prolonged, and sub-ileus and hypoglycemia were observed. GHRP-2 increased the feeling of hunger and food intake, decreased early satiety and improved hypoglycemia. The patient's body weight gradually increased by 6.7 kg (from 21.1 kg to 27.8 kg) in 14 months after starting GHRP-2 administration. The fatigability and muscle strength improved, and the physical and mental activities were also increased. No obvious side effects were observed after long-term intranasal administration of GHRP-2.ConclusionsPatients with a long-term history of eating disorder occasionally recover from the psychological problems such as fear for obesity but remain emaciated. We believe that ghrelin agonists such as GHRP-2 may be promising agents for the effective treatments of severe anorexia nervosa in a chronic condition.
机译：摘要背景技术在日本，生长激素释放肽2（GHRP-2）在临床上被用作生长激素分泌不足的诊断剂，但是GHRP-2在神经性厌食症中的治疗应用尚未得到研究。据报道，GHRP-2对Ghrelin受体具有激动作用并增加食物摄入量。方法我们对患有20年神经性厌食病史的患者给予GHRP-2，以确定GHRP-2治疗是否会增加食物摄入量和体重。 GHRP-2在每顿饭前通过鼻内途径给药1年。结果尽管该患者报告了我们先前的治疗减少了进食的恐惧并降低了对瘦身的渴望，但由于消化道，她无法增加食物摄入量或体重功能障碍。饭后呕吐由于胃排空延迟和无法治愈的便秘而延长，并观察到亚回肠和低血糖。 GHRP-2可增加饥饿感和食物摄入量，降低早饱感并改善低血糖症。开始服用GHRP-2后的14个月内，患者体重逐渐增加了6.7 kg（从21.1 kg增至27.8 kg）。疲劳性和肌肉力量得到改善，身体和精神活动也增加。长期鼻内施用GHRP-2后未观察到明显的副作用。结论具有长期饮食失调史的患者偶尔会从心理问题中恢复，例如对肥胖的恐惧，但仍然消瘦。我们认为，ghrelin激动剂（例如GHRP-2）可能是在慢性病中有效治疗严重神经性厌食症的有前途的药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号